Alpha 2.0
Login Register
» Authors » Reyes Bernabe Caro

Reyes Bernabe Caro

Explore the profile of Reyes Bernabe Caro including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 16
Citations 2145
Followers 0
Related Specialties
Oncology
Pulmonary Medicine
General Medicine
Top 10 Co-Authors
Mariano Provencio
Jong-Seok Lee
Margarita Majem
Martin Reck
Alex Martinez-Marti
Manuel Domine
Delvys Rodriguez-Abreu
Amelia Insa
Julie R Brahmer
Suresh S Ramalingam
Published In
J Thorac Oncol
Lung Cancer
J Clin Oncol
N Engl J Med
Clin Transl Med
Affiliations
Soon will be listed here.
Recent Articles
1.
Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort A
Besse B, Goto K, Wang Y, Lee S, Marmarelis M, Ohe Y, et al.
J Thorac Oncol . 2025 Jan; PMID: 39755170
Introduction: Treatment options for patients with EGFR-mutated NSCLC with disease progression on or after osimertinib and platinum-based chemotherapy are limited. Methods: CHRYSALIS-2 cohort A evaluated amivantamab plus lazertinib in patients...
2.
Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis
Peters S, Paz-Ares L, Reck M, Carbone D, Brahmer J, Borghaei H, et al.
J Thorac Oncol . 2024 Oct; 20(1):94-108. PMID: 39369790
Introduction: Nivolumab plus ipilimumab-based treatment regimens have shown long-term, durable efficacy benefits in patients with metastatic NSCLC. Here we report clinical outcomes from a pooled analysis of patients with metastatic...
3.
Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study
Reck M, Dziadziuszko R, Sugawara S, Kao S, Hochmair M, Huemer F, et al.
Lung Cancer . 2024 Sep; 196:107924. PMID: 39306923
Objectives: IMbrella A is a Phase III extension study that allowed rollover from Roche/Genentech-sponsored atezolizumab trials, including IMpower133, a Phase I/III trial of first-line atezolizumab or placebo plus carboplatin/etoposide in...
4.
Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP
Ospina A, Bolufer Nadal S, Campo-Canaveral de la Cruz J, Gonzalez Larriba J, Macia Vidueira I, Massuti Sureda B, et al.
Clin Transl Oncol . 2024 Mar; 26(7):1647-1663. PMID: 38530556
Introduction: Recent advances in the treatment of locally advanced NSCLC have led to changes in the standard of care for this disease. For the selection of the best approach strategy...
5.
Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1
Reck M, Ciuleanu T, Lee J, Schenker M, Zurawski B, Kim S, et al.
J Thorac Oncol . 2023 May; 18(8):1055-1069. PMID: 37146754
Introduction: In CheckMate 227 Part 1, nivolumab plus ipilimumab prolonged overall survival (OS) versus chemotherapy in patients with metastatic NSCLC, regardless of tumor programmed death-ligand 1 (PD-L1) expression. Here, we...
6.
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227
Brahmer J, Lee J, Ciuleanu T, Bernabe Caro R, Nishio M, Urban L, et al.
J Clin Oncol . 2022 Oct; 41(6):1200-1212. PMID: 36223558
Purpose: We present 5-year results from CheckMate 227 Part 1, in which nivolumab plus ipilimumab improved overall survival (OS) versus chemotherapy in patients with metastatic non-small-cell lung cancer, regardless of...
7.
Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817
Paz-Ares L, Ciuleanu T, Pluzanski A, Lee J, Gainor J, Otterson G, et al.
J Thorac Oncol . 2022 Sep; 18(1):79-92. PMID: 36049658
Introduction: We characterized the safety of first-line nivolumab plus ipilimumab (NIVO+IPI) in a large patient population with metastatic NSCLC and efficacy outcomes after NIVO+IPI discontinuation owing to treatment-related adverse events...
8.
Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial)
Provencio M, Serna-Blasco R, Nadal E, Insa A, Garcia-Campelo M, Casal Rubio J, et al.
J Clin Oncol . 2022 May; 40(25):2924-2933. PMID: 35576508
Purpose: Neoadjuvant chemotherapy plus nivolumab has been shown to be effective in resectable non-small-cell lung cancer (NSCLC) in the NADIM trial (ClinicalTrials.gov identifier: NCT03081689). The 3-year overall survival (OS) and...
9.
RESILIENT part 1: a phase 2 dose-exploration and dose-expansion study of second-line liposomal irinotecan in adults with small cell lung cancer
Paz-Ares L, Spigel D, Chen Y, Jove M, Juan-Vidal O, Rich P, et al.
Cancer . 2022 Feb; 128(9):1801-1811. PMID: 35195913
Background: RESILIENT (NCT03088813) is a phase 2/3 study assessing the safety, tolerability, and efficacy of liposomal irinotecan monotherapy in patients with small cell lung cancer and disease progression on/after first-line...
10.
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial
Paz-Ares L, Ramalingam S, Ciuleanu T, Lee J, Urban L, Bernabe Caro R, et al.
J Thorac Oncol . 2021 Oct; 17(2):289-308. PMID: 34648948
Introduction: In CheckMate 227, nivolumab plus ipilimumab prolonged overall survival (OS) versus chemotherapy in patients with tumor programmed death-ligand 1 (PD-L1) greater than or equal to 1% (primary end point)...